Centogene
96 articles with Centogene
-
CENTOGENE Receives FDA Emergency Use Authorization for SARS-CoV-2 RT-PCR Assay for Individuals Without Symptoms or Other Reasons to Suspect COVID-19
10/19/2020
Centogene N.V., a commercial-stage company focused on rare diseases that transforms real-world clinical and genetic data into actionable information for patients, physicians, and pharmaceutical companies, announced that the U.S. Food and Drug Administration has issued Emergency Use Authorization for ‘CentoSure’, the company's latest SARS-CoV-2 RT-PCR test.
-
Collaboration Between CENTOGENE and U-Diagnostics Increases COVID-19 Testing Capacities in the Netherlands
10/14/2020
Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on rare diseases that transforms real-world clinical and genetic data into actionable information for patients, physicians, and pharmaceutical companies, and U-Diagnostics B.V., a Dutch medical laboratory, specialized in analysis in the field of clinical chemistry and hematology, medical microbiology, medical immunology
-
CENTOGENE’s Information Security Management System Awarded ISO/IEC 27001:2017 Accreditation
9/28/2020
Centogene N.V. announced that that the Company has been awarded ISO/IEC 27001:2017 certification following an extensive audit of its Information Security Management System.
-
CENTOGENE Reports First Half 2020 Financial Results
9/23/2020
Centogene N.V., a commercial-stage company focused on rare diseases that transforms real- world clinical and genetic data into actionable information for patients, physicians, and pharmaceutical companies, provided an update on its corporate progress and reported its financial results for the three and six months ended June 30, 2020.
-
CENTOGENE Opens Walk-In COVID-19 Testing Facility at Düsseldorf Airport
9/23/2020
Centogene N.V., a commercial-stage company focused on rare diseases that transforms real-world clinical and genetic data into actionable information for patients, physicians, and pharmaceutical companies, announced the opening of its new COVID-19 testing facility at Düsseldorf Airport.
-
CENTOGENE to Report First Half 2020 Financial Results on September 23, 2020
9/16/2020
Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on rare diseases that transforms real-world clinical and genetic data into actionable information for patients, physicians, and pharmaceutical companies, today announced that it will issue a press release reporting its financial results for the six months ended June 30, 2020 on Wednesday, September 23, 2020, and will host a conference call to
-
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for September 11, 2020.
-
CENTOGENE Publishes Huge Dataset That Supports Genome Sequencing as a First-Line Diagnostic Test
9/3/2020
Centogene N.V., a commercial-stage diagnostics and genetic research company, announced that its scientific publication ‘Successful application of genome sequencing in a diagnostic setting: 1,007 index cases from a clinically heterogeneous cohort’ has appeared in the European Journal of Human Genetics - one of the world's leading medical genetic journals.
-
Evotec and Centogene Expand Collaboration into Gaucher Disease
8/20/2020
CENTOGENE AND EVOTEC INTEND TO IDENTIFY NOVEL DISEASE-MODIFYING TARGETS FIRST TARGET SELECTED FOR THE DEVELOPMENT OF A THERAPEUTIC CANDIDATE CENTOGENE CONTRIBUTES ACCESS TO ITS GLOBAL PROPRIETARY RARE DISEASE PLATFORM, EVOTEC WILL LEVERAGE ITS PROPRIETARY IPSC PLATFORM AND DRUG DISCOVERY AND DEVELOPMENT EXPERTISE HAMBURG and ROSTOCK, GERMANY / ACCESSWIRE / August 20, 2020 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) and CENTOGENE N.V. (Nasdaq:CNTG
-
CENTOGENE and Evotec Expand Collaboration Into Gaucher Disease
8/20/2020
Centogene N.V. and Evotec SE announced that the two companies have expanded their existing drug discovery partnership related to Gaucher disease – a genetic lysosomal storage disorder caused by mutations in the glucocerebrosidase gene.
-
CENTOGENE Opens Walk-In COVID-19 Testing Facility at Hamburg Airport
8/19/2020
Centogene N.V., a commercial-stage company focused on rare diseases that transforms real-world clinical and genetic data into actionable information for patients, physicians, and pharmaceutical companies, announced the opening of its new walk-in COVID-19 test facility at Hamburg Airport.
-
CentoMD® Update Reveals Further Insights Into Rare Diseases
8/11/2020
Centogene N.V. announced a release of CentoMD® 5.8 ̶ the latest update of the Company’s curated mutation database for rare diseases including epidemiologic, phenotypic, and clinical data.
-
BioSpace Global Roundup, Aug. 6
8/6/2020
Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines. -
CENTOGENE Supports Tajikistan in Fight Against the COVID-19 Pandemic
8/4/2020
CENTOGENE expands ongoing development cooperation with Ministry of Health and Social Protection of the Population of Tajikistan (MoH) to now include COVID-19 testing
-
CENTOGENE and Molecular Health Announce an Exclusive Collaboration With the Aim to Transform the Development of Orphan Drugs
7/27/2020
The combination of real-life data sets in rare diseases with innovative big data/artificial intelligence/novel scientific computational knowledge will transform biomedical research, product development, and therapy. R eal-life data and I nnovative B ioinformatic A lgorithms (RIBA project) will enable the creation of a powerful environment to accelerate, de-risk, and improve the development of new orphan drugs for many diseases and disease areas. RIBA develops and offers data-/computing-dri
-
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for July 24, 2020.
-
CENTOGENE Announces Convenient At-Home Coronavirus Test Solution Now Available in Germany on Online Marketplace
7/23/2020
CENTOGENE announced that its validated COVID-19 test kit, called CentoKit-19™, is now available in Germany on Amazon.de.
-
CENTOGENE Announces the Scientific Publication of a holistic solution in the preventive testing of COVID-19
7/9/2020
Centogene N.V., a commercial-stage diagnostics and genetic research company, announced that its paper ‘Rapid Large-Scale COVID-19 Testing During Shortages’ has been published in Diagnostics, an international peer-reviewed open access journal on medical diagnosis.
-
CENTOGENE Announces Pricing of Primary and Secondary Public Offering of Common Shares
7/9/2020
Centogene N.V. (Nasdaq: CNTG) (“Centogene” or the “Company”), a commercial-stage company focused on rare diseases that transforms real-world clinical and genetic data into actionable information for patients, physicians, and pharmaceutical companies, announced today the pricing of its primary and secondary public offering of 3,500,000 common shares of the Company, consisting of 2,000,000 common shares
-
CENTOGENE Announces Proposed Primary and Secondary Public Offering of Common Shares
7/7/2020
Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on rare diseases that transforms real-world clinical and genetic data into actionable information for patients, physicians, and pharmaceutical companies, announced today that it and certain selling shareholders have commenced an underwritten public offering of 3,500,000 common shares of the Company,